Post-chemotherapy cognitive impairment medical therapy

Post-chemotherapy cognitive impairment Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Post-chemotherapy cognitive impairment from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Post-chemotherapy cognitive impairment medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Post-chemotherapy cognitive impairment medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Post-chemotherapy cognitive impairment medical therapy
CDC on Post-chemotherapy cognitive impairment medical therapy
Post-chemotherapy cognitive impairment medical therapy in the news
Blogs on Post-chemotherapy cognitive impairment medical therapy
Directions to Hospitals Treating Post-chemotherapy cognitive impairment
Risk calculators and risk factors for Post-chemotherapy cognitive impairment medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Treatment

Hypothesized treatment options include the use of antioxidants, cognitive behavior therapy, erythropoietin and stimulant drugs such as methylphenidate, though as the mechanism of PCCI is not well understood the potential treatment options are equally theoretical.

Modafinil, approved for narcolepsy, has been used off-label in trials with people with symptoms of PCCI. Modafinil is a wakefulness-promoting agent that can improve alertness and concentration, and studies have shown it to be effective at least among women treated for breast cancer.

While estrogen hormone supplementation may reverse the symptoms of PCCI in women treated for breast cancer, this carries health risks, including possibly promoting the proliferation of estrogen-responsive breast cancer cells.